Synopsis:

This Pharmaceutical stock is in the news today following the announcement of a strong Q2 result with 73 percent growth in profits and 24 percent growth in its revenue along with Strong performance in the US market.

The shares of this company which is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions were in news today as company declared its Q2 results with strong performance metrics and growth in international business.

With a market cap of Rs 89,842 crore, the shares of Lupin Ltd g

See Full Page